menu toggle

September 13, 2023

Now available BRIXADI™

BRIXADI™ (buprenorphine) extended-release injection, for subcutaneous use, is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.


Please see full prescribing information.

PLEASE NOTE: To access these BRIXADI products you must enroll and become certified in the BRIXADI REMS.